Success Metrics

Clinical Success Rate
73.3%

Based on 44 completed trials

Completion Rate
73%(44/60)
Active Trials
26(20%)
Results Posted
30%(13 trials)
Terminated
16(12%)

Phase Distribution

Ph phase_3
2
2%
Ph phase_2
20
15%
Ph phase_4
3
2%
Ph early_phase_1
9
7%
Ph phase_1
16
12%
Ph not_applicable
41
32%

Phase Distribution

25

Early Stage

20

Mid Stage

5

Late Stage

Phase Distribution91 total trials
Early Phase 1First-in-human
9(9.9%)
Phase 1Safety & dosage
16(17.6%)
Phase 2Efficacy & side effects
20(22.0%)
Phase 3Large-scale testing
2(2.2%)
Phase 4Post-market surveillance
3(3.3%)
N/ANon-phased studies
41(45.1%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

71.0%

44 of 62 finished

Non-Completion Rate

29.0%

18 ended early

Currently Active

26

trials recruiting

Total Trials

130

all time

Status Distribution
Active(37)
Completed(44)
Terminated(18)
Other(31)

Detailed Status

Completed44
unknown31
Recruiting18
Terminated16
Not yet recruiting11
Active, not recruiting8

Development Timeline

Analytics

Development Status

Total Trials
130
Active
26
Success Rate
73.3%
Most Advanced
Phase 4

Trials by Phase

Early Phase 19 (9.9%)
Phase 116 (17.6%)
Phase 220 (22.0%)
Phase 32 (2.2%)
Phase 43 (3.3%)
N/A41 (45.1%)

Trials by Status

active_not_recruiting86%
not_yet_recruiting118%
unknown3124%
recruiting1814%
terminated1612%
withdrawn22%
completed4434%

Recent Activity

Clinical Trials (130)

Showing 20 of 130 trialsScroll for more
NCT04518748Phase 1

Combined Y-90 Selective Internal Radiation Therapy (Y-90 SIRT) and Stereotactic Body Radiation Therapy (SBRT) in Hepatic Malignancy.

Active Not Recruiting
NCT02886585Phase 2

Pembrolizumab In Central Nervous System Metastases

Active Not Recruiting
NCT03204123Phase 2

PSMA PET Imaging of Recurrent Prostate Cancer

Active Not Recruiting
NCT07690917

A Study of a New PET Scanner in People With Cancer

Recruiting
NCT04788043Phase 2

Study of Magrolimab and Pembrolizumab in Relapsed or Refractory Classic Hodgkin Lymphoma

Terminated
NCT04018053Early Phase 1

18Fluorine-Fluciclovine PET/CT for Staging Muscle Invasive Bladder Cancer Preceding Radical Cystectomy

Completed
NCT06636175Early Phase 1

64Cu-LLP2A for Imaging Hematologic Malignancies

Recruiting
NCT07325253Phase 2

A Pilot Study to Correlate 4-18F- Fluoro-1-naphthol 18F-4FN PET/CT Imaging With Chronic Graft Versus Host Disease Manifestations

Recruiting
NCT05994014Not Applicable

PET/CT* vs. Cardiac CT for Detecting Coronary Atherosclerotic Disease [*PET: Positron Emission Tomography; CT: Computed Tomography]

Recruiting
NCT07523997

Imaging of Endometriosis With Total-body PET-CT (PET-Endo)

Recruiting
NCT05513027Not Applicable

Augmented Whole-body Scanning Via Magnifying PET/CT (AWSM-PET/CT) Techniques Abilities to Improve Upon the Diagnostic Accuracy of the Standard-of-care (SOC) PET/CT for Malignant Lesion Detection

Terminated
NCT03851237Phase 1

CCR2 PET for Pancreatic Cancer Imaging and Prediction of Response to Standard and CCR2-Targeted Therapy

Completed
NCT07285993Phase 2

Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET

Not Yet Recruiting
NCT06941480Phase 1

A Study of 177Lu-DTPA-SC16.56 in People With Neuroendocrine Carcinomas of the Lung and Prostate

Not Yet Recruiting
NCT04668872

Biopsy After Radioembolization to Identify Changes in Tumor Cells From the Radiation

Recruiting
NCT03195777Not Applicable

Novel PET/CT and Treatment Strategies to Reduce PTS Following DVT

Completed
NCT07243873

Synthetic PET From CT Improves Precision Diagnosis and Treatment of Lung Cancer: a Prospective, Observational, Multicenter Study

Recruiting
NCT06479187Phase 4

PSMAtrack-tracking Changes in PSMA-PET During Initial Therapy for Metastatic Hormone-sensitive Prostate Cancer

Active Not Recruiting
NCT06062745Phase 1

Pilot Study for Detection of PSMA-Low CRPC-NE Tumors With Fluciclovine PET/CT

Recruiting
NCT02633111

DNA Sequencing-Based Monitoring of Minimal Residual Disease to Predict Clinical Relapse in Aggressive B-cell Non-Hodgkin Lymphomas

Active Not Recruiting

Drug Details

Intervention Type
DIAGNOSTIC TEST
Total Trials
130